Multiple strategies have been implemented worldwide to fight the burden of the pandemic caused by COVID-19, with vaccination being one of the most promising.1 Notably, the first vaccine to be authorized in Italy was the BNT162 mRNA-based vaccine, which has also been approved in the USA, United Kingdom, and Canada.1,2 As a matter of fact, RNA vaccines are immunogenic and cost-effective.1
Local reactions to the second dose of the BNT162 COVID-19 vaccine / Tammaro, A.; Adebanjo, G. A. R.; Parisella, F. R.; De Marco, G.; Rello, J.. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 34:4(2021). [10.1111/dth.15000]
Local reactions to the second dose of the BNT162 COVID-19 vaccine
Tammaro A.;Adebanjo G. A. R.;De Marco G.;
2021
Abstract
Multiple strategies have been implemented worldwide to fight the burden of the pandemic caused by COVID-19, with vaccination being one of the most promising.1 Notably, the first vaccine to be authorized in Italy was the BNT162 mRNA-based vaccine, which has also been approved in the USA, United Kingdom, and Canada.1,2 As a matter of fact, RNA vaccines are immunogenic and cost-effective.1File allegati a questo prodotto
| File | Dimensione | Formato | |
|---|---|---|---|
|
Tammaro_Local-reactions_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
479.15 kB
Formato
Adobe PDF
|
479.15 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
